References
Taveira-DaSilva AM, Steagall WK, Moss J (2006) Lymphangioleiomyomatosis. Cancer Control 13:276–285
Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G (2005) Sirolimus for Kaposi’s sarcoma in renal transplant recipients. N Engl J Med 352:1317–1323
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140–151
McCormack FX, Inoue Y, Moss J et al; for the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595–1606
Sodhi A, Montaner S, Patel V, Gómez-Román JJ, Li Y, Sausville EA, Sawai ET, Gutkind JS (2004) Akt plays a central role in sarcomagenesis induced by Kaposi’s sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 6:4821–4826
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stallone, G., Infante, B., Tartaglia, L. et al. Renal angiomyolipomatosis and Kaposi’s sarcoma: a possible link disrupted by sirolimus. Intern Emerg Med 7 (Suppl 2), 127–129 (2012). https://doi.org/10.1007/s11739-012-0833-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-012-0833-6